Multidirectional anti-melanoma effect of galactolipids (MGDG-1 and DGDG-1) from Impatiens parviflora DC. and their synergy with doxorubicin.
Antineoplastic Agents
/ chemistry
Biphenyl Compounds
/ chemistry
Cell Line, Tumor
Cell Survival
/ drug effects
Doxorubicin
/ pharmacology
Drug Synergism
Glycolipids
/ chemistry
Humans
Impatiens
Melanoma
/ drug therapy
Monophenol Monooxygenase
/ antagonists & inhibitors
Mutagenicity Tests
Picrates
/ chemistry
Skin Neoplasms
/ drug therapy
Vibrio
/ drug effects
Anti-melanoma
Anti-tyrosinase
Combined therapy
Digalactosyl diacylglycerol (DGDG)
Impatiens
Monogalactosyl diacylglycerol (MGDG)
Journal
Toxicology in vitro : an international journal published in association with BIBRA
ISSN: 1879-3177
Titre abrégé: Toxicol In Vitro
Pays: England
ID NLM: 8712158
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
07
05
2021
revised:
08
07
2021
accepted:
31
07
2021
pubmed:
7
8
2021
medline:
21
1
2022
entrez:
6
8
2021
Statut:
ppublish
Résumé
The anti-melanoma potential of galactolipids: MGDG-1 and DGDG-1, isolated from Impatiens parviflora, and their synergistic effect with anticancer drug - doxorubicin (DOX) was investigated. Both compounds demonstrated time- and dose-dependent cytotoxicity against human melanoma cells of different metastatic potential. MGDG-1 was more effective than DGDG-1, with the highest activity against A375 cell line (IC
Identifiants
pubmed: 34358613
pii: S0887-2333(21)00156-9
doi: 10.1016/j.tiv.2021.105231
pii:
doi:
Substances chimiques
1-O-linolenoyl-2-O-hexadeca-7,10,13-trienoyl-3-O-galactopyranosylglycerol
0
3-O-(6-O-galactopyranosylgalactopyranosyl)-1,2-di-O-dodecanoylglycerol
0
Antineoplastic Agents
0
Biphenyl Compounds
0
Glycolipids
0
Picrates
0
Doxorubicin
80168379AG
1,1-diphenyl-2-picrylhydrazyl
DFD3H4VGDH
Monophenol Monooxygenase
EC 1.14.18.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105231Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.